Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.
The investigational aldosterone synthase inhibitor lorundrostat demonstrated efficacy in reducing systolic blood pressure and ...
Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) ...
Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to ...
Vixarelimab showed rapid, sustained itch reduction and good safety in prurigo nodularis. Learn more about the study and ...
Re-treatment with ligelizumab is effective and generally well tolerated in patients with chronic spontaneous urticaria who ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback